CO2019006693A2 - Composición mejorada de lansoprazol y simeticona y proceso para prepararla - Google Patents

Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Info

Publication number
CO2019006693A2
CO2019006693A2 CONC2019/0006693A CO2019006693A CO2019006693A2 CO 2019006693 A2 CO2019006693 A2 CO 2019006693A2 CO 2019006693 A CO2019006693 A CO 2019006693A CO 2019006693 A2 CO2019006693 A2 CO 2019006693A2
Authority
CO
Colombia
Prior art keywords
simethicone
lansoprazole
prepare
improved composition
microgranules
Prior art date
Application number
CONC2019/0006693A
Other languages
English (en)
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CO2019006693A2 publication Critical patent/CO2019006693A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2019/0006693A 2016-12-14 2019-06-21 Composición mejorada de lansoprazol y simeticona y proceso para prepararla CO2019006693A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016016587A MX2016016587A (es) 2016-12-14 2016-12-14 Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
PCT/IB2017/057904 WO2018109693A1 (fr) 2016-12-14 2017-12-13 Composition améliorée de lansoprazol et de siméticone et procédé de préparation de cette dernière

Publications (1)

Publication Number Publication Date
CO2019006693A2 true CO2019006693A2 (es) 2019-07-10

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006693A CO2019006693A2 (es) 2016-12-14 2019-06-21 Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Country Status (9)

Country Link
AR (1) AR110183A1 (fr)
BR (1) BR112019011966A2 (fr)
CL (1) CL2019001462A1 (fr)
CO (1) CO2019006693A2 (fr)
CR (1) CR20190290A (fr)
DO (1) DOP2019000145A (fr)
MX (1) MX2016016587A (fr)
PE (1) PE20191654A1 (fr)
WO (1) WO2018109693A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (fr) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques orales de siméthicone
BR112014014278A2 (pt) * 2011-12-14 2017-06-13 Disphar Int B V composição farmacêutica

Also Published As

Publication number Publication date
AR110183A1 (es) 2019-03-06
BR112019011966A2 (pt) 2019-11-05
WO2018109693A1 (fr) 2018-06-21
MX2016016587A (es) 2018-06-13
DOP2019000145A (es) 2019-08-15
PE20191654A1 (es) 2019-11-07
CR20190290A (es) 2019-11-18
CL2019001462A1 (es) 2019-08-23

Similar Documents

Publication Publication Date Title
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
PE20151301A1 (es) Formulaciones farmaceuticas resistentes a la manipulacion indebida
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
UY36518A (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CO2019006693A2 (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
ECSP19044926A (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения
ECSP16086746A (es) Formulación inmunosupresora